Illustration: Radina Dobrinova for Endpoints News
January 17, 2024 03:51 AM ESTUpdated 08:08 AM
Diagnostics
Law

Rav­gen con­tin­ues its le­gal re­venge saga with a $57M ver­dict over Nat­era

Jared Whitlock

Features Editor

Rav­gen, a com­pa­ny that was a blip in pre­na­tal screen­ing not long ago, has con­tin­ued its streak of le­gal vic­to­ries against much larg­er com­pa­nies thanks …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times